{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008491","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.370650+00:00","generated_at":"2026-06-01T12:30:15.638190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ReShape Lifesciences Q1 rev $1.9M (-15% YoY), gross margin up to 59.9%, opex down 51%","bullets":["Q1 revenue $1.9M, down 15% YoY; gross margin improved to 59.9% (from 53.5%) due to lower overhead.","Total operating expenses down 51% YoY; sales & marketing down 53%, G&A down 56%.","Cost reduction plan expected to cut 2024 opex by ~55% vs 2023; RIF implemented.","Cash and equivalents $2.5M; net working capital $4.4M.","Lap-Band 2.0 FLEX launch underway; intragastric balloon patent issued; M&A search with Maxim Group."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008491","json":"https://secwatch.observer/filing/0001558370-24-008491.json","markdown":"https://secwatch.observer/filing/0001558370-24-008491.md","text":"https://secwatch.observer/filing/0001558370-24-008491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000155837024008491/0001558370-24-008491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000155837024008491/rsls-20240515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T12:30:15.638190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}